FDA approves first-in-class targeted therapy daraxonrasib for metastatic pancreatic cancer

The approval introduces the first RAS(ON) inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma with a KRAS G12X mutation, establishing a new biomarker-directed option for one of the hardest-to-treat cancers.

The US Food and Drug Administration (FDA) has approved daraxonrasib for adults with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) whose tumours harbour a KRAS G12X mutation, making it the first approved RAS(ON) inhibitor and the first targeted therapy for this patient population.

The decision establishes a new treatment option for patients whose disease has progressed following earlier systemic therapy and makes molecular testing for eligible KRAS mutations increasingly relevant to treatment selection.

Field	Content
Alert Type	Drug Approval
Drug Name	Daraxonrasib
Indication	Treatment of adults with previously treated metastatic pancreatic ductal adenocarcinoma harbouring a KRAS G12X mutation
Therapy Area(s)	Oncology; Pancreatic cancer
Geography	United States (FDA)
What Happened	The FDA has approved daraxonrasib, a first-in-class RAS(ON) inhibitor, for adults with previously treated metastatic PDAC whose tumours contain a KRAS G12X mutation. The approval establishes the first targeted treatment specifically available for this molecularly defined pancreatic cancer population. Daraxonrasib is designed to inhibit multiple oncogenic RAS variants in their active, or “ON”, state, distinguishing its mechanism from earlier mutation-specific KRAS inhibitors.
Why It Matters	KRAS alterations are found in the large majority of pancreatic ductal adenocarcinomas, but historically there have been few opportunities to directly target the underlying RAS biology. Approval of daraxonrasib provides a biomarker-directed treatment for a subset of patients with metastatic disease after prior therapy and represents an important clinical validation of targeting active RAS signalling in pancreatic cancer.
Supporting Context	Pancreatic cancer remains one of the most difficult solid tumours to treat, particularly once disease becomes metastatic. Daraxonrasib was developed to target active RAS proteins across several KRAS G12X variants rather than a single mutation, potentially allowing treatment of a broader molecular population than mutation-specific KRAS therapies. Patients must undergo appropriate molecular testing to determine whether their tumours carry an eligible KRAS G12X alteration.
Key Takeaway	Daraxonrasib’s approval establishes the first targeted therapy for KRAS G12X-mutated metastatic pancreatic cancer and marks the first regulatory approval for the RAS(ON) inhibitor class.
What to Watch	Commercial rollout and adoption of daraxonrasib, the effect of the approval on routine KRAS molecular testing in pancreatic cancer, and ongoing studies evaluating RAS(ON) inhibition in earlier treatment settings, additional tumour types and combination regimens.
Primary Source	US Food and Drug Administration
Relevant Date	26 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com